Race signs global distribution agreement with Durbin PLC
Filed with ASX · · 2 pages · English
Earlier from Racura Oncology
- Race increases placement to $3.69m
- Race completes over-subscribed $3.159 million placement
- Second Bisantrene Patent Allowed in US
- Notice of Allowance for Bisantrene Patent in US
- Race Receives $170k R&D Tax Incentive Refund
Later from Racura Oncology
- Race executes agreement for Bisantrene clinical trial
- RAC cancer drug success in AML reported by French doctors
- Bisantrene approval in UK for supply as unlicensed medicine
- Bisantrene poster presented at French Leukaemia Conference
- FDA Grants Bisantrene Rare Paediatric Disease Designation
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology